3-dimethylcarbamoyloxy-tri-N-methyl-anilinium; iodide | 1212-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-dimethylcarbamoyloxy-tri-N-methyl-anilinium; iodide
• 英文别名: 3-Dimethylcarbamoyloxy-tri-N-methyl-anilinium; Jodid；Ammonium, (3-(dimethylcarbamoyloxy)phenyl)trimethyl-, iodide；[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;iodide
• CAS: 1212-37-9
• 化学式: C₁₂H₁₉N₂O₂*I
• 分子量: 350.2
• InChiKey: IRBBYXNXNPIQLI-UHFFFAOYSA-M

物化性质

• 熔点：
  167 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -1.05
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N,N-二甲基氨基甲酸3-(二甲基氨基)苯酯 、 碘甲烷 生成 3-dimethylcarbamoyloxy-tri-N-methyl-anilinium; iodide
  参考文献：
  名称：

  DE535835

  摘要：

  公开号：

文献信息

• Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
  申请人：DAS-MG, Inc.

  公开号：US11389420B2

  公开（公告）日：2022-07-19

  The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.

  本发明描述了一种 NK1-拮抗剂与新斯的明的恒定组合使用，通过提供治疗有效的溴化新斯的明或硫酸甲酯每日剂量而无剂量限制性胃肠道不良反应，从而促进对患有重症肌无力的患者的治疗。
• PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND A NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS
  申请人：DAS-MG, Inc.

  公开号：US20200155495A1

  公开（公告）日：2020-05-21

  The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.
• USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONING
  申请人：CLARENCE-SMITH Kathleen E.

  公开号：US20200147068A1

  公开（公告）日：2020-05-14

  The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects.
• PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS
  申请人：DAS-MG, Inc.

  公开号：US20220331284A1

  公开（公告）日：2022-10-20

  The present invention describes the administration of an NK1 antagonist, in combination with neostigmine methylsulfate, intravenously, via subcutaneous infusion, or both intravenously and via subcutaneous infusion to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects associated with neostigmine methylsulfate.
• [EN] NEOSTIGMINE COMBINATION AND COMPOSITIONS<br/>[FR] COMBINAISON DE NÉOSTIGMINE ET COMPOSITIONS
  申请人：GT BIOPHARMA INC

  公开号：WO2018140412A1

  公开（公告）日：2018-08-02

  The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose that attenuates or even abrogates the dose-limiting gastrointestinal adverse effects of neostigmine.